ow level laser therapy and magnetotherapy as coadjuvant in bisphosphonate related osteonecrosis of the jaws.

Not Applicable

Recruiting

• Conditions: Bisphosphonate Related Osteonecrosis of the Jaws; C05.116.852

• Registration Number: RBR-494fyn
• Lead Sponsor: niversidade Nove de Julho

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-04-22
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: Female
• Target Recruitment: Not specified

Inclusion Criteria

Consent to participate in the study through a Free and Informed Consent Form signed by the patient, female, 60 years of age or older, using oral Alendronate sodium, with weekly doses of 70mg for at least 2 years. continuously for the prevention and or treatment of osteopenia or osteoporosis.
Presence of jaw osteonecrosis, in stages 1 or 2, according to the AAOMS classification. Patients who have previously undergone oral cavity surgical procedures, such as dental extractions or implants, performed no more than 6 months prior to the occurrence of osteonecrosis.

Exclusion Criteria

Presence of jaw osteonecrosis at stage 0 or 3, according to AAOMS.
Presence of spontaneous osteonecrosis in the jaws.
Pathological fractures by osteonecrosis.
Use of alendronate for less than two years or discontinued.
Need to use synthesis material (plate and screws).
Indication of the use of alendronate sodium due to malignant neoplasms, bone metastases, Paget's disease or any indication other than osteoporosis or osteopenia.
Patients undergoing head and neck radiotherapy in the last 5 years.
Patients undergoing hyperbaric chamber sessions in the last 2 years.
Patients with blood dyscrasias, renal failure, liver failure, cardio respiratory failure, immune deficiency, malignant neoplasms, AIDS or septicemia.

Study & Design

• Study Type: Intervention
• Study Design: Not specified